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Objectives . The purpose of this study was to examine the
incidence and clinical implications of throwtbocytopenia that oc-
curs in hospital after administration of throinkAytic therapy for
acute myocardial infarction .
Background. The use of thrombolytic therapy in patients with
acute myocardial infarction has improved mortality rates, but
hemorrhage remains a major complication . Because thrombocy-
topenia may be associated with hemorrhage after thrombolytic
therapy, we examined the incidence and clinical implications of
thrombocytopenin after administration of thrombolytic therapy
for acute myocardial infarction .
Methods. The patient population comprised 1,001 patients
enrolled in Phases 2, 3 and 5 of the Thromboysis and Angioplasty
in Myocardial Infarction (T I) trial and the urokinase trial .
Patients received recombinant tissue-type plasminogen activator,
urokinase or combination therapy in various dosing schemes . All
patients received heparin, aspirin and a calcium-channel blocking
agent. Thrombocytopenia occurring anytime after thrombolytic
therapy was defined as a nadir platelet count either <100,000/pi
or <1/2 baseline . Blood loss was quantified by a bleeding index .
Multiple logistic regression was used to evaluate the independent
The use of thrombolytic therapy in patients with acute
myocardial infarction has improved mortality rates (1-4) but
is not without risks . Hemorrhage is the major complication
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contribution of thrombocylopenla in a model predicting in .
hospital mortality .
Results . Thrombocytopenia occurred in 16 .4% of patients,
with no difference among the thrembolyfic regimens . Patients
with thrombocytopenia had a lower median acute ejection fraction
and a higher likelihood of three-vessel coronary artery disease
than patients without thromhocylopenia, Patients with thro
cytopenia had more hemorrhage, a higher in-hospital mortality
rate and a more complicated hospital course than patients without
thrombecytopenia, even after consideration of other important
variables, including age, acute ejection fraction, number of dis-
eased vessels, bypass surgery and use of intraaortic balloon
counterpulsation .
CG?aelusiow . Thrombocytopenia after thrombolytic therapy IE
a common event and is associated with excess hemorrhage and
mortality . Platelet counts should be monitored daily after
admit-
istration of thrombolytic therapy because the appearance of
thrombocytopenia identifies a subset of patients at increased risk
for hemorrhage and death.
(J Am Coil Cardiol 1994;23 .891-8)
of thrombolytic therapy, with bleeding being reported in 5%
to 30% of treated patients (5-8) . 'Various groups hive
attempted to define risk factors for hemorrhage in these
patients, examining both clinical characteristics and henie-
static variables (5-9) . All previous reports concur that the
use of invasive procedures increases the risk of bleeding,
presumably because of the inability of the lytic agent to
distinguish pathologic coronary thromLus from hemostatic
plug at a vascular access site .
Most studies have concentrated on the coagulation aspect
of hemostasis, finding only weak relations between markers
of systemic lysis and bleeding (10) . Relatively little attention
has been given to the role of platelet number and function
Add= for cornspodente : r . Robert A . Harrington, Division of
Cardiology, P .O
. Box 31217, Duke University Medical Center, Durham,
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Table 1 . Thrombolysis and Angioplasty in Myocardial Infarction
Phase 2 Trial Thrombolytic Regimens
*Ten percent of recombinant tissue-type plasminogen activator (rt-PA)
given as a bolus. U
K = urokinase .
during the course of thrombolytic therapy (11) . Bovill et al .
(8) have recently reported that thrombocytopenia was sig-
nificantly associated with major hemorrhage in the nonsur-
gical group of patients treated in the conservative arm of the
Thrombolysis in Myocardial Infarction (TIM[) Phase 2 trial .
To further examine the clinical significance of thrombocyto-
penia, the present study was undertaken, using prospec-
tively collected information on platelet counts and clinical
outcomes in a large acute myocardial infarction data base, to
determine its incidence in the subsequent hospital phase
after thrombolytic therapy for acute myocardial infarction
and whether it is associated with excess hemorrhage and
mortality.
Methods
Patient population. The patient population comprised
1,001 patients enrolled in Phases 2, 3 and 5 of the Throm-
bolysis and Angioplasty in Myocardial Infarction (TAMI)
trial (12-14) and the urokinase trial (15) . Patients eligible for
enrollment had chest pain symptoms consistent with myo-
cardial infarction lasting 6 h and an electrocardiogram
(ECG) demonstrating al mm (0 .1 mV) of ST segment
elevation in at least two contiguous leads . Exclusion criteria
included age >75 years ; previous Q wave infarction in the
same ECG distribution; recent stroke, trauma or major
surgery; active bleeding or bleeding predisposition ; uncon-
trolled hypertension; and prolonged cardiopulmonary resus-
citation (CPR) and cardiogenic shock .
Thrombollytic regimens. Patients were treated with re-
combinant tissue-type plasminogen activator (rt-PA), uroki-
nase or combination therapy in \arious dosing regimens .
Patients enrolled in the TAMI 2 study received various
combinations of rt-PA and urokinase, as shown in Table 1 .
Both drugs were administered for I h . Patients in the TAMI
3 study received 1 .5 mgikg body weight of WPA for 4 h, with
1.0 m&g (up to 90 mg) during the first hour and 0 .5 mg/kg
(up to 45 mg) during the next 3 h . Patients in the TAMI 5
study received one of three drug regimens : urokinase, 3 MU
(1.5-MU bolus, then 1 .5 MU for 90 min) ; rt-PA, 100 mg
(6-mg bolus
. 54 me for the first hour, 20 mg/h for the next
2 h) ; or combination therapy (urokinase, 1
.5 MU, for 1 It and
rt-PA, 1 mg/kg "maximum 90 mg], for 1 h) . In the urokinase
trial, the first 61 patients received 3 MU of urokinase for 45
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to 60 min, and the subsequent 41 patients received a 1 .5-MU
bolus followed by 1 .5 MU for 45 to 60 min .
Catheterization strategies. All patients in the TAMI 2 and
3 studies and the urokinase trial underwent cardiac catheter-
ization 90 min after initiation of thrombolytic therapy to
determine vessel patency . The TAMI 5 study, which exam-
ined the timing of cardiac catheterization in acute myocar-
dial infarction, randomized half of the patients to undergo a
90-min catheterization and half to deferred predischarge
catheterization. At acute 90-min catheterization, rescue an-
gioplasty of the infarct-related artery was performed for
occluded vessels (TIMI flow grade 0 to 1) or for ongoing
ischemia with a patent vessel (TIMI flow grade 2 to 3) .
Patients underwent repeat catheterization with angiography
and ventriculography before discharge .
Medical management . All patients received intravenous
heparin within several hours of thrombolytic therapy (range
0 to 180 min) . Heparin therapy was adjusted to achieve a
patient activated partial thromboplastin time of 1 .5 to 2 .5
times control levels . Patients were treated with intravenous
heparin for at least 24 h and up to 7 to 10 days . All enrolled
patients received aspir.a(325 mg orally) daily . All patients
received a calcium channel blocking agent (either diltiazem,
30 to 60 mg three to four times daily, or nifedipine, 20 mg
three times daily). Patients were not given beta-blocking
agents unless indicated for hypertension, arrhythmiaa or
refractory symptoms of ischemia .
Platelets and blood loss. Platelet counts, measured as
platelets per microliter, were determined at enrollment and
subsequently at the investigator's discretion . The lowest
measured absolute value was considered the nadir platelet
count. Thrombocytopenia was defined by a nadir platelet
count either <100,00011A or <1/2 baseline. Blood loss was
quantified by a bleeding index intended to estimate the total
number of units of blood lost: units of packed red blood ,.-ells
transfused plus the change in hematocrit divided by 3 ,16) .
Excluded patients. Because of inadequate collection of
platelet count data, 127 patients were excluded from review,
leaving 874 patients for analysis . The majority of excluded
patients (119 patients) did not have a baseline platelet count
recorded . There was no significant difference between pa-
tients with and without adequate platelet count data with
regard to baseline clinical characteristics, extent of coronary
disease, acute ejection fraction or change in hematocrit .
Statistical methods. Continuous variables are represented
by the median value and the interquartile range (25th to 75th
percentiles). Discrete variables are described in terms of
percents . The distribution of selected baseline characteris-
tics and the occurrence of clinical outcomes in patients who
did versus those who did not develop thrombocytopenia
were compared with the use of the chi-square test or the
Fisher exact test for discrete variables and the Wilcoxon
rank-sum test for continuous variables . To further examine
the relation between thrombocytopenia and bleeding, a
multiple linear regression model was used to predict the
bleeding index . A set of factors previously identified as
n-PA UK
Group 1(n = 14) 25 mg 0.5 MU
Group 2 (n = 20) 25 mg It MU
Group 3 In = 24)* 1 .0 mgTg 15 MU
Group 4 0 = 33? 1
.0 mm/kg 1 .0 MU
GMT 5 0 = Q* 1
.0 mg/kg 2.0 MU
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Figure 1. Empiric cumulative
distribution of the baseline and
nadir platelet counts in all pa-
tients (pts) and cumulative distri-
bution function of the nadir
platelet counts in the nonsurgical
group only .
significant predictors of bleeding (6) v . re included in a
regression model in combination with a variable representing
the occurrence of thrombocytopenia . Statistical analysis was
performed for all patients as well as the subset of patients not
requiring coronary bypass surgery, Similarly, logistic multi-
ple regression was used to evaluate the independent contri-
bution of thrombocytopenia in a previously determined
model predicting in-hospital mortality when known predic-
tors, such as age, systolic blood pressure, infarct location,
acute ejection fraction, number of diseased vessels, the use
of coronary bypass surgery and intraaortic balloon counter-
pulsation, were included .
Results
Incidence and timing of thrombocytopenia . Figure 1
shows the empiric cumulative distribution function of the
baseline and nadir platelet counts in all patient groups as well
as the cumulative distribution function of the nadir platelet
counts in only the nonsurgical group . Thrombocytopenia
occurred in 143 patients (16 .4%), with 64 patients (7 .3%)
experiencing a nadir platelet count <100,0001AL In the
nonsurgical group, thrombocytopenia occurred in 55 (h .1%)
of 676 patients, 24 of whom (3 .6%) had a nadir platelet count
<100,00011AI .
There was no difference in the incidence of thrombocy-
topenia among thrombolytic regimens . Thrombocytopenia
occurred in 16.4% of patients treated with rt-PA monother-
apy, in 19 .1% of patients treated with urokinase monother-
apy and in 14.1% of patents treated with combination
therapy .
The time to nadir platelet count was collected only in the
TAMI 5 study (577 patients), where it occurred at a median
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of 4 days after thrombolytic therapy administration (Fig . 2) .
The median time to nadir platelet count in the nonsurgical
group was 3 days,
aseline patient characteristics . Baseline clinical charac-
teristics of the two groups (thrombocytopenia and no throm-
bocytopenia) are shown in Table 2 . Patients with thrombo-
cytopenia had a lower median acute ejection fraction (p :s
0.0001) and a higher likelihood of three-vessel coronary
artery disease (p
:5 0.0001) than patients without thrombo-
cytopenia. In the nonsurgical group, patients with thrombo-
cytopenia also had a lower median acute ejection fraction
(41% vs. 53%) and a higher likelihood of three-vessel coro-
nary artery disease (27% vs . 9%) compared with patients
without thrombocytopenia .
Hemorrhage . More hemorrhage, including a highly sig-
nificant decrease in the hematocrit (p < 0.0001), occurred in
patients with thrombocytopenia than in patients without
thrombocytopenia in the entire group, as well as in the
nonsurgical group (Table 3) . There were two intracranial
hemorrhages in the thrombocytopenia group and six in the
group without thrombocytopenia (1 .4% vs. 0.8%, p = 0 .62) .
Even in the presence of other factors, including age and
need for bypass surgery and intraaortic balloon counterpul-
sation, thrombocytopeniaa was independently associated
with a higher bleeding index (Table 4A), second only to the
need for bypass surgery . A similar analysis was undertaken
in the nonsurgical group, revealing that thrombocytopenia
was the variable most strongly related to the risk of bleeding,
as estimated by the bleeding index (Table 4B) .
Mortality and other clinical outcomes
. Clinical outcomes
of patients with and without thrombocytopenia are shown in
Table 5. Patients with thrombocytopeniaa had a significantly
higher in-hospital mortality than patients without thrombo-
814
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cytopenia. In patients with nadir platelet counts < 100,OWA.
the in-hospital mortality was 21 .9%. Examination of the
nonsurgical group showed similar findings, with a higher
in-hospital mortality among patients with thrombocytopenia
(23.6% vs. 3.5%). In a logistic regression analysis that
alusted for ape, acute ejection fraction, number of diseased
vessels and use of bypass surgery and intraaortic balloon
counterpulsation, thrombocytopenia remained indepen-
dently associated with higher in-hospital mortality (p ---
0.0059) .
Patients with thrombocytopenia also had a higher inci-
dence of congestive heart failure, recurrent ischemia and
complete heart block and were more likely to have under-
TAk 2. Clinical Characteristics
0-1
2
3
27%
30%
43%
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Figure 2. Time to nadir platelet count, as
collected in the Thrombolysis and Angio-
plasty in Myocardial Infarction Phase 5
trial .
gone bypass surgery, balloon pump insertion and endotra-
cheal intubation than those without thrombocytopenia . The
thrombocytopenic group had both a longer intensive care
unit stay as well as a longer hospital stay than the group
without thrombocytopenia .
Wmadon
Out results indicate that thrombocytopenia usually oc-
curs in the early hospital phase in patients treated with
thrombolysis for acute myocardial infarction, especially in
patients requiring bypass surgery or intraaortic balloon
pump placement. or both. There is a significant increase in
59%
28%
13%
< 0 .0001
Values presented are median value, with interquartile range (25th to 75th percentile) in parentheses, or percent
.
Thrombocytopenia
(n = 143)
No Thrombocytopertia
(n - 731) p Value
Age (yr) 61(54,68) 57(49,65) < 0 .0001
Male gender 70%
81% O.OD6
Race
White
92a 89% 0 .63
Black
9%
Other
0% 2%
Hypertension
49% 42%
0,14
Diabetes mellitus
16% 16% 0 .94
Flypespidemia
19% 23% 0 .39
T*mw use in past 5 yr 55%
6rr/V 0 .11
Peripheral vascular disease 5%
0 .073
Cerebrovascular disease 3% 2%
0 .50
Acute ejection fraction (%)
44(32,55) 52(45,59)
0 .
1 :1 u
I
No
. of , ?!,: --Js diseased
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Table 3 . Hemorrhage Variabl
Values presented are median values, with interquartile range (25th to 75th percentile) in parentheses . PRBCs = packed red blood cells
: pt = patient .
blood loss, as quantified by a bleeding index, in patients with
thrombocytopenia compared with patients without thrombo-
cytopenia. In-hospital mortality, in both surgical and non-
surgical groups, is higher among patients with thrombocyto-
penia, even after consideration of other important prognostic
variables .
Previous reports. In a report on hemorrhage in the TIMI
I group, Rao et 1 . (5) noted that thrombocytopenia (defined
as a platelet count < 150,000/td) occurred in 14 (4 .8%) of 240
patients, but they did not examine the contribution of
thrombocytopenia to bleeding tendency . In an analysis of
the conservatively treated patients in the TIMI 11 study,
Bovill et al . (8) noted that thrombocytopenia (defined as a
platelet count
:5100,0001AI) occurred in 21 (1 .5%) of 1,395
patients and was significantly associated with major hemor-
rhagic risk. The overall incidence of thrombocytopenia in all
3,339 patients was only 1 .6%, but platelet counts were
Table 4. Variables in Regression Model Associated With Excess
Hemorrhage
Regression Coefficient
	
F p Value
CABG = coronary artery bypass grafting ; IABP = intraaortic balloon
pump; PTCA = percutaneous coronary angioplasty ; rt-PA = tissue-type
plasminogen activator.
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available for at least 5 days in only 1,600 patients (47
.9%),
and some thrombocytopenia may have been missed
. Our
overall incidence of thrombocytopenia, defined by either
criterion, was much higher at j6 .4% on the basis of data from
87.3% of enrolled patients . Although previous reports have
defined thrombocytopenia as a platelet count either
~~100,000/pl (8) or <150,0004d (5), we chose to use two
definitions for our analysis . There are no clear data indicat-
ing what level of thrombocytopenia may significantly disrupt
hemostasis, particularly in a patient group treated with a
variety of coagulation- and platelet-altering drugs, including
thrombolytic therapy, heparin, aspirin, nitroglycerin and
intravenous contrast dye . A decrease in platelet count >1/2
baseline most likely indicates some adverse effect on platelet
physiology and warrants inclusion in an analysis of the
consequences of thrombocytopenia . When the definition of
thrombocytopenia was restricted to a platelet count
< 100,0001AI, we still found an incidence of 7 .3%. Our higher
incidence of thrombocytopenia might reflect the aggressive
therapy used, including acute cardiac catheterization, bal-
loon counterpulsation and bypass surgery . In the subset of
patients from the TAMI 5 study, where the time to nadir
platelet count was available, the lowest platelet count oc-
curred at a median of 4 days .
Thrombocytopenia and hemorrhage . Not surprisingly,
patients with thrombocytopenia had- a higher amount of
blood loss than patients without thrombocytopenia . This
finding was not solely due to the need for surgery because it
held true for the nonsurgical group as well . Our results
confirm the findings of Bovill et al . (8) that thrombocyto-
peniaa after the administration of thrombolytic therapy is
associated with a significant amount of excess hemorrhage,
even after consideration of other important variables, such
as bypass surgery, intraaortic balloon counterpulsation and
age .
Thrombocytopenia and mortality. Although the increased
hemorrhagic risk associated with thrombocytopenia is not
unexpected, the relation between thrombocytopenia and
in-hospital mortality in both surgical and nonsurgical groups
is an unexpected finding . The significant correlation of
thrombocytopenia with the invasive modalities of balloon
All Patients Nonsurgical Group
Thrombocytopenia
(n = 143)
No Thrombocytopenia
(11 7.11 p Value
Thrombocytopenia
(n = 55)
No Thrombocytor .-nia
(n = 621)
p We
Baseline hematocrit 43 (39 . 46) 44 (41 .46) 0A14 42 0, 46) 44 (41 .46) 0m0
Nadir hematocrit 25 (29 . 28) 34 cc P) < 0.0001 27 C4 . 3)) 350434 < yowl
Baseline-nadir hematocrit 17(13,21) 10(7 . 14) * 0.0001 13(10, 17) 9(6 . 12) < 0 .0001
Transfusions (PRBCs)
U/pt 0(0.0) < 0.0001 2(0 .4) o(yo) < 0 .0001
4 ", 8)
>2 U
62% 9% < 0.0001 42% 3% < 0 .0001
Bleeding index 10.0 (6 .5 . 14 .0) 3 .3 (2 .3, 5 .0) < 0 .0001 6 .2 (4,0, 9 .8) 3 .1 (2 .2, 4 .2) < 0 .6001
A . All Patients
CABG 5 .39 351 .41 < 0.0001
Thrombocytopenia 3 .28 88 .7 < 0.0001
IABP 2 .95 47 .4 < 0.0001
Age (yr) 0.042 14 .3 < 0.0002
PTCA 0.33 1 .3 0.25
rt-PA 0.36 2 .5 0.11
Acute Catheterization 0.70 7 .6 0.0058
Female gender 0.69 6 .4 0.011
B. Nonsurgical Group
Thrombocytopenia 3 .83 102 .1 < 0.0001
IABP 2 .20 24 .1 < 110001
Age (yr) 0.042 18 .3 < 0.0001
PTCA 0.094 0 .14 0.70
rt-PA 0.36 3 .12 0.048
Acute catheterization 0.64 7 .8 0.0054
Female gender 0.56 5 .4 0.020
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pump and bypass surgery raises the possibility that throm-
bocytopenia is a nonspecific marker of severity of illness .
Support for this hypothesis is evident in the lower ejection
fractions and the higher incidence of three-vessel coronary
artery disease in the thrombocytopenic group . However, our
logistic regression model demonstrates that thrombocytope-
nia identifies a patient subgroup at risk for increased mor-
tality even after consideration of other clinical characteris-
tics that have been measured .
Etiology of thrombocytopenia . The occurrence of throm-
bocytopenia after thrombolytic therapy is most likely a
multifactorial phenomenon. Because all of the patients re-
ceived heparin within the 1st 24 h of admission, heparin-
induced thrombocytopenia must be considered a cause
(17,18) . The estimated incidence of heparin-induced throm-
bocytopenia in the typical heparin-treated patient is between
1 .3% and 5.4% (19) . This immune-mediated process usually
occurs between 5 and 10 days after initiation of therapy,
leads to a mild to severe decrease in platelet count and may
be complicated by either hemorrhage or thrombosis (17,18) .
The timing of nadir platelet counts in our patient population
is consistent with heparin-induced thrombocytopenia . How-
ever, given our observed incidence of thrombocytopenia of
16.4%, heparin is unlikely to be responsible for all of the
thrombocytopenia.
Thrombocytopenia is a known complication of intraaortic
balloon counterpuLation and most likely contributes to the
risk of hemorrhage associated with use of the device (20) .
We found a high incidence of thrombocytopenia in patients
requiring intraaortic balloon pump placement . The proposed
mechanisms for intraaortic balloon pump-induced thrombo-
cytopenia include platelet consumption secondary to local
thrombus formation, decreased platelet survival time sec-
ondary to mechanical trauma to platelets and increased
platelet consumption as a result of disseminated intravascu-
lar coagulation (20) .
*Not recorded for urokinase trial
. Values presented are median values, with interquartile range (25th to 75th
percentile) in parentheses, or percent
. CCU = coronary care unit .
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Patients with thrombocytopenia had a high incidence of
bypass surgery, and patients requiring bypass surgery had a
high incidence of thrombocytopenia . It has been known for
>20 years that cardiopulmonary bypass can lead to a de-
crease in platelet counts, probably because of mechanical
trauma and local consumption (21-25) . A recent review
estimates that platelet counts will decrease by -50% from
preoperative levels after initiating cardiopulmonary bypass
and will remain depressed for several postoperative days
(25) . There is little doubt that thrombocytopenia and abnor-
mal platelet function can contribute to postoperative hemor-
rhage after bypass surgery (24-26) .
The possible contributory role of the thrombolytic agent
and the fibrinolytic state should be considered . Activation of
the fibrinolytic system can have a variety of effects on
platelet function (11), but little information is available on
platelet number. It is known that both streptokinase and
tissue-type plasminogen activator can activate platelets (27-
30), perhaps through the generation of thrombin (31-34) .
Paradoxically, thrombolysis and the fibrinolytic state can
also inhibit platelet function . Mechanisms for the antiplatelet
effect of thrombolytic therapy include the disruption of
platelet aggregation through lysis of fibrinogen bound to
platelets (35), the cleavage of membrane receptor glycopro-
tein Ib (36,37) and the creation of fibrin(ogen) degradation
productions that inhibit aggregation . Thus, thrombolytic
therapy can reduce platelet function as well as number,
exacerbating hemorrhagic complications . Finally, although
some animal studies have suggested that platelet survival
time is decreased in the presence of plasmin (36,38), studies
in humans receiving urokinase for the treatment of pulmo-
nary embolism showed no such decrease in platelet survival
time (39).
Limitations of the present study. There are limitations to
this study. We did not show that thrombocytopenia occur-
ring after thrombolytic therapy causes more bleeding or
Table 5. Clinical Outcomes
Thrombocytopenia
(n = 143)
No Thrombocytopenia
(n = 731) p value
In-hospital mortality
16 .1% 3.3% < 0.0001
Congestive heart failure 38%
14% < 0.0w!
Recurrent ischemia 33%
1817c < 0 .0001
Complete heart block 21% 10% < MOW
Emergency bypas , surgery 15% 1 .5% < 0.0001
Any bypass surgery
62% 15% < 0.0001
Emergency angioplasty 16% 9% 0.025
Acute angioplasty 25%
21% 0.23
Any angioplasty 41% 53% 0.008
Balloon pump insertion 35% 3.4% < 0.0001
Endotracheal intubation 38% 6% < 0
.0001
(not intraope .ative or postoperative)
Length of CCU stay (days) 3 (2 .5) 2(2,3) < 0.0001
Length of hospital stay (days) 12(9, 19)
9(8. 12) < 0.0001
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more in-hospital deaths . Rather, we showed an association
that may or may not be causal . It would be inappropriate
from these analyses to claim causality because in some
patients, certain of the clinical events that were demon-
strated to be associated with thrombocytopenia (e .g ., revas-
cularization) actually preceded the development of throm-
bocytopenia. Because of the methods of data collection, we
were only able to adjust our regression analysis for the
baseline characteristics of patients and not for the status at
the time of nadir thrombocytopenia . For example, a patient
developing reocclusion on the third hospital day with car-
diogenic shock is represented in the regression model as
being in the baseline state at the initial time of the myocardial
infarction . In a similar fashion, it is very difficult to prove
any particular cause of thrombocytopenia in these patients
given the complexity of the hospital course, the numerous
medications involved and the variability of procedures per-
formed. Determination of heparin-induced antibody forma-
tion would be interesting and helpful in sorting out the
possible mechanisms of the thrombocytopenia .
We chose to focus on the association of thrombocytope-
nia with adverse clinical events after thrombolytic therapy
and did not test an association with other disruptions in the
hemostatic system, including the extent of activated partial
thromboplastin time prolongation, the level of fibrinogen
depletion or an increase in fibrin degradation products .
Previous studies have only been able to demonstrate a weak
relation between the extent of fibrinogen depletion and
bleeding complications (5,6,8,13) .
Conclusions . Thrombocytopenia that occurs in the hos-
pital phase after administration of thrombolytic therapy is a
common event . Whatever the reasons for the decline in
platelet counts, our data indicate that thrombocytopenia is a
potent predictor of excess hemorrhage and mortality in the
treated patient. Whether interventions designed to prevent
or correct thrombocytopenia will translate into an improve-
ment in patient outcome is uncertain . Until these issues are
further resolved, platelet counts should be monitored daily
after administration of thrombolytic therapy because the
appearance of thrombocytopenia identifies a subset of pa-
tients at increased risk for hemorrhage and death .
We acknowledge Kerry Bassett for assistance with graphics, Penny Hodgson
for critical review of the manuscript, and we thank Linda Sherman and Pearl
Slow for assistance with manuscript preparation.
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